

Support for Brain Stimulation Therapies Wavering

BY SHERRY BROSCHEIT
San Francisco Bureau

RANCHO MIRAGE, CALIF. — Two of the newer brain stimulation treatments for chronic depression took hits from the federal government in recent actions, Dr. William McDonald said at the annual meeting of the American College of Psychiatrists.

As a result, vagal nerve stimulation (VNS) may become less available, and it's unlikely that transcranial magnetic stimulation (TMS) will be approved any time soon, said Dr. McDonald, J.B. Fuqua Professor of Psychiatry and Behavioral Sciences at Emory University, Atlanta.

The Centers for Medicare and Medicaid Services is reconsidering whether to continue covering the cost of VNS, which was approved for treatment of chronic depression in a controversial decision by the Food and Drug Administration in 2005, he said.

The data backing use of VNS were not strong. An open committee of the FDA recommended against approval, but the device

The lack of data backing the use of VNS for depression and the possible loss of Medicare coverage make the treatment a tough sell for many clinicians.

was approved in a closed committee with the contingency that the device's maker conduct follow-up studies of safety and efficacy, said Dr. McDonald, a consultant and speaker for Cyberonics, which markets the VNS device, and for Neuro-

Netics, which makes the TMS machine.

"If Medicare doesn't pay for VNS, it's unclear who will pay for it," he said. So far, all of the patients treated with VNS at his institution have been either young and disabled or older patients who were insured under Medicare.

Although initial open-label pilot data made VNS look promising, the primary outcomes of a subsequent randomized, placebo-controlled study of 235 patients "were nothing but disappointing," he said. After 8 weeks of treatment, there was no significant difference in response rates measured by the Hamilton Rating Scale for Depression (HRSD₂₄) in the VNS group compared with patients randomized to sham treatment.

There was a significant difference, however, in a secondary measure of outcome. With the Inventory of Depressive Symptomatology, Self-Report (IDS-SR₃₀), the VNS group showed a 17% response rate, compared with 8% of the sham group.

A separate, open-label study of 329 patients who were followed for a year after receiving the VNS implant in clinical trials and continued other treatments without modifications during that time showed impressive response rates that persuaded the FDA to approve the device, said Dr. McDonald, who is also director of the Fuqua Center for Late-Life Depression at Emory. With VNS, 30% of these patients responded to treatment and 17% went into remission, com-

pared with 13% and 7%, respectively, of patients whose depression would be expected to respond or remit with observation and no other treatment modifications.

The data don't answer key questions for clinicians considering VNS therapy, Dr. McDonald noted, such as which patients are best to send for VNS. For example, his institution performs 250 ECT procedures as maintenance therapy each month, but there are no data to show whether patients on maintenance ECT might benefit from


VNS, which would be simpler and more practical, if effective.

Considering that VNS therapy costs \$20,000-\$30,000 and requires that psychiatrists learn new information for treatment and follow-up, the lack of data and possible loss of Medicare coverage make VNS a tough sell for many clinicians.

As for TMS, an open committee of the FDA declined to approve the device in January 2007 based on randomized, controlled trial data. The data failed to show

efficacy in its primary outcome measure but (like VNS) did show efficacy by a secondary measure.

Response rates were not significantly different between the TMS and sham groups when measured by the Montgomery-Asberg Rating Scale. But when measured by the HRSD₂₄, over 30% in the TMS group responded and 20% went into remission. A new trial sponsored by the National Institutes of Health is using MRI-guided TMS to see if this will improve results. ■



FOR THE EFFICACY YOUR PATIENTS WITH CONGESTION EXPECT...

Mucinex^D

IS AVAILABLE
BEHIND THE
PHARMACY
COUNTER

The MUCINEX D formula has not changed


- MUCINEX D clears nasal congestion & relieves sinus pressure due to colds or allergies¹
- Pseudoephedrine HCl shrinks swollen nasal mucosa, keeping nasal passages open²
- The bi-layer tablet, with immediate- and extended-release guaifenesin, thins and loosens mucus for 12 hours³

Encourage your patients to get the nasal congestion relief they expect by asking their pharmacist for **MUCINEX D**¹

Find additional information at www.adamsrt.com.

Use as directed.

References: 1. Mucinex D product labeling. 2. Hamilton LH, Chobanian SL, Cato A, Perkins JG. A study of sustained action pseudoephedrine in allergic rhinitis. *Ann Allergy*. 1982;48:87-92. 3. Data on file [Mucinex NDA], Adams Respiratory Therapeutics, Chester, NJ.



ADAMS
RESPIRATORY
THERAPEUTICS™

© 2006 Adams Respiratory Therapeutics, Fort Worth, TX 76155
192 REV. 122106

Mucinex^D

600 mg guaifenesin and 60 mg pseudoephedrine HCl
extended-release bi-layer tablets

